文献类型：期刊文献

英文题名：Lung cancer and the Gut-microbiota-lung Axis: emerging evidence and potential clinical implications

作者：Liu, Li[1];Yang, Li[2];Zhang, Hongdu[1];Li, Hongmin[1];Shang, Tianlu[1];Liu, Lihan[1]

第一作者：刘立;刘莉;刘丽;刘黎

通信作者：Liu, LH[1]

机构：[1]Gansu Univ Chinese Med, Affiliated Hosp 3, Dept thorac Surg, Baiyin, Peoples R China;[2]Gansu Univ Chinese Med, Affiliated Hosp 3, Dept Oncol, Baiyin, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp 3, Dept thorac Surg, Baiyin, Peoples R China.|[10735]甘肃中医药大学;

年份：2025

卷号：12

外文期刊名：FRONTIERS IN MEDICINE

收录：;Scopus(收录号：2-s2.0-105024070492);WOS:【SCI-EXPANDED(收录号:WOS:001631949400001)】；

基金：The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by the First People's Hospital of Baiyin College Scientific Research Project (project number: 2021YK-01; Project Name: Clinical Research on Thoracoscopic Lobectomy and Aegmentectomy in the Treatment of Early Lung Cancer).

语种：英文

外文关键词：lung cancer; Gut-microbiota-lung Axis; gut microbiota; immunotherapy; short-chain fatty acids; gut dysbiosis

摘要：Lung cancer remains the leading cause of cancer-related deaths globally, with a 5-years survival rate of only around 20%. Merging cohort and Mendelian-randomization studies indicate that gut dysbiosis is associated with-though not yet proven to cause-an elevated risk and worse prognosis of non-small-cell lung cancer. Lower fecal abundance of butyrate producers such as Faecalibacterium prausnitzii and expansion of Enterobacteriaceae correlate with reduced systemic CD8 + T-cell infiltration and shorter progression-free survival during immune-checkpoint blockade. Antibiotic exposure within 30 days before anti-PD-1 initiation is consistently linked to diminished objective response and overall survival in retrospective cohorts, whereas supplementation with butyrogenic probiotics or fecal microbiota transplantation from responders restores therapeutic efficacy in pre-clinical models. This review integrates epidemiological, mechanistic and clinical data to clarify the current evidence, identify gaps and outline the steps needed to translate gut-lung-axis research into safe, effective adjunctive therapies for patients with lung cancer.